Cytovene (ganciclovir) / Roche 
Welcome,         Profile    Billing    Logout  
 268 Diseases   30 Trials   30 Trials   2139 News 


12345678910111213...3536»
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Case report: Autoimmune encephalomyelitis following cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. (Pubmed Central) -  Jun 14, 2024   
    Here we report a case of possible AE following CMV viremia after allo-HSCT, which was successfully treated with high-dose pulsed methylprednisolone and intravenous immunoglobulins (IVIg)...The patient developed CMV viremia on day 36 after transplantation, and serum CMV-DNA remained positive after initiating ganciclovir antiviral therapy, turning negative one month later...The mechanisms of AE after allo-HSCT and the relationship with CMV infection should be further studied. Therefore, reporting this and similar cases will improve our awareness and understanding of the underlying disease mechanisms.
  • ||||||||||  Cytovene (ganciclovir) / Roche, ProstAtak (aglatimagene besadenovec) / Candel Therap, Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
    Clinical, Review, Journal, Gene therapy:  Gene therapy for people with hepatocellular carcinoma. (Pubmed Central) -  Jun 5, 2024   
    The impact of gene therapy on adverse events needs to be investigated further. Evidence on the effect of gene therapy on health-related quality of life is lacking.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche, Livtencity (maribavir) / Takeda, GSK
    Preclinical, Journal:  A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation. (Pubmed Central) -  Jun 4, 2024   
    Here, we describe one such mAb, which was found to target gH/gL envelope complexes and effectively limit HCMV infection and dissemination. Further, administration of the antibody in combination with the antiviral drug ganciclovir inhibited HCMV in a synergistic manner, highlighting this approach and the use of anti-HCMV mAbs more broadly, as a potential therapeutic strategy for the treatment of diverse patient populations.
  • ||||||||||  Journal:  Management of cytomegalovirus reactivation in patient with immunotherapy-induced gastritis. (Pubmed Central) -  Jun 4, 2024   
    We present the case of a 52-year-old woman diagnosed with stage IV clear cell renal cell carcinoma who received combination of surgery and systemic therapy with nivolumab (anti-PD1) and ipilimumab (anti-CTLA-4)...CMV viral load by quantitative PCR in plasma was 2,000 IU/mL so intravenous ganciclovir was prescribed...Second-line treatment with Anti-TNF was performed using a single-dose regimen of intravenous infliximab 5 mg/Kg. Finally, the patient presented a clinical and endoscopic response and a negative CMV DNA test in the blood after completing the antiviral treatment.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  HHV6-Associated Hydrocephalus in a Pediatric Hematopoietic Stem Cell Transplant Recipient: An Unusual Presentation. (Pubmed Central) -  Jun 4, 2024   
    In addition to accompanying imaging findings, the patient tested positive for HHV-6 by PCR from both serum and CSF samples and demonstrated dramatic improvement with the institution of steroid therapy in addition to ganciclovir treatment. The availability of rapid diagnostic measures in addition to a multidisciplinary approach is crucial to manage HHV-6 encephalitis and associated complications in HSCT patients.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
    Letermovir Outperforms Valganciclovir in Mitigating Leukopenia Risks: A Comparative Analysis in Post-Lung Transplant Patients (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_992;    
    The incidence of CMV breakthrough was similar in patients receiving valganciclovir or letermovir, and patients receiving letermovir did not experience neutropenia. Letermovir appears a practical alternative for CMV prophylaxis after lung transplantation and may obviate need for management of neutropenia with costly granulocyte colony stimulating factors
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche, Livtencity (maribavir) / Takeda, GSK
    Clinical, Review, Journal:  Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. (Pubmed Central) -  May 3, 2024   
    Prophylaxis with antiviral medications reduces CMV disease and CMV-associated death, compared with placebo or no treatment, in solid organ transplant recipients. These data support the continued routine use of antiviral prophylaxis in CMV-positive recipients and CMV-negative recipients of CMV-positive organ transplants.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1. (Pubmed Central) -  May 2, 2024   
    However, higher doses of GCV and TFT prevented drug resistance in the resistance selection experiments. In summary, we identified novel mutations conferring resistance to nucleoside analogs, including TFT, and proposed that GCV + TFT combination therapy may be an effective strategy to prevent the development of drug resistance.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
    Journal, Machine learning:  Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning. (Pubmed Central) -  Apr 26, 2024   
    These results can inform healthcare decision-makers on the most effective use of their resources for post-transplant refractory CMV treatment. The ML algorithms exhibit good performances in comparison with previously validated models and should be evaluated prospectively.
  • ||||||||||  Cytovene (ganciclovir) / Roche, RZ-001 / Rznomics
    Anti-Cancer Efficacy and Safety of hTERT Splicing Ribozyme-based RNA Editing Therapy for Glioblastoma Multiforme (Exhibit Hall) -  Apr 22, 2024 - Abstract #ASGCT2024ASGCT_2593;    
    RZ-001 treatment combined with ganciclovir (GCV) induced cytotoxicity in human GBM cells in a dose-dependent manner...Importantly, RZ-001 administration followed by GCV treatment efficiently improved median survival rate in PDX model established with tumor tissues from recurrent and temozolomide (TMZ)-resistant GBM patient, compared with groups treated with control or TMZ...Recently, RZ-001 received Fast Track designation from US FDA for GBM patients. This study and recent recognitions by the US FDA may raise the potential of splicing ribozyme-based RNA editing approaches as a safe and effective therapeutic option for patients with highly unmet medical needs.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Cytomegalovirus infection as a rare cause of colitis. (Pubmed Central) -  Apr 18, 2024   
    Suspected CMV infection in a immunosuppressed by chemotherapy patient, he was treated with ganciclovir. The patient presented clinical improvement, without fever or diarrhea and improvement of the punch ulcers in the endoscopic controls, so he could be discharged from the hospital with follow-up in the outpatient consulting offices.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Review, Journal:  Herpes simplex keratitis: A brief clinical overview. (Pubmed Central) -  Apr 15, 2024   
    Clinicians should be informed about triggers and advised on measures to minimize the risk of reactivation. In summary, the recurrent nature of HSK underscores the importance of both acute and long-term management strategies to preserve corneal health and maintain optimal visual function.
  • ||||||||||  Review, Journal:  Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current Approaches. (Pubmed Central) -  Mar 19, 2024   
    Foscarnet, cidofovir, and maribavir are treatments for refractory or resistant-CMV. Selection of CMV antiviral treatment should be determined by patient-specific factors, including severity of illness, resistant or refractory disease, dose-limiting adverse effects, and the preferred route of administration.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Folate-Targeted Nanocarriers Co-Deliver Ganciclovir and miR-34a-5p for Combined Anti-KSHV Therapy. (Pubmed Central) -  Mar 17, 2024   
    The co-loaded dual-drug nanocomplex not only inhibits the proliferation and migration of KSHV-positive cells but also decreases the mRNA expression level of KSHV lytic and latent genes. In conclusion, this co-loaded dual-drug nanocomplex may provide an attractive strategy for antiviral drug delivery and anti-KSHV therapy.
  • ||||||||||  temozolomide/perillyl alcohol conjugate (NEU001) / NeOnc Technologies, NeuCen BioMed, perillyl alcohol (NEO100) / NeOnc Technologies
    Journal:  Activation of Epstein-Barr Virus' Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide. (Pubmed Central) -  Mar 13, 2024   
    Inclusion of the antiviral agent ganciclovir synergistically enhanced the cytotoxic impact of NEO212, pointing to a potential combination treatment for EBV-positive cancers which should be explored further. Overall, our study establishes NEO212 as a novel agent able to stimulate EBV's lytic cycle in NPC tumors, with implications for other virus-associated cancers.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Powassan Virus Infection Presenting as Rapidly Progressive Encephalitis and New-onset Refractory Status Epilepticus (NORSE) (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_4202;    
    CSF studies were notable for elevated protein and HHV-6 IgM antibodies and was empirically treated with Ganciclovir...While neuroinvasive Powassan virus remains a rare disease process, it should be considered on the differential for patients with NORSE in an endemic tick region. Additionally, it should be considered with isolated T2/FLAIR changes without diffusion restriction, particularly when the deep white matter structures are involved.
  • ||||||||||  Journal:  Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis. (Pubmed Central) -  Mar 6, 2024   
    Additionally, it should be considered with isolated T2/FLAIR changes without diffusion restriction, particularly when the deep white matter structures are involved. We report a case of cytomegalovirus colitis in a pediatric patient with pancolitis who had been refractory to aminosalicylate, infliximab, and ustekinumab and was in clinical remission and with transmural response on upadacitinib...He developed an acute increase in symptoms and did not respond to therapy escalation with increased upadacitinib 45